

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Act of 1934

Date of Report (Date of earliest event reported): APRIL 6, 2001

PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other
jurisdiction
of incorporation)

000-17085
(Commission
File Number)

95-3698422
(I.R.S. Employer
Identification No.)

14272 FRANKLIN AVENUE, SUITE 100
TUSTIN, CALIFORNIA
(Address of principal executive offices)

92780-7017
(Zip Code)

Registrant's telephone number, including area code: (714) 508-6000

ITEM 5. OTHER EVENTS.

On April 6, 2001, Peregrine Pharmaceuticals, Inc., a Delaware corporation (the "Registrant"), elected Edward J. Legere to the offices of President and Chief Executive Officer following the resignation of Dr. John Bonfiglio.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEREGRINE PHARMACEUTICALS,
INC.

Date: April 17, 2001

By: /s/ Edward J. Legere

Edward J. Legere,
President and Chief Executive Officer